Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQ2Y7L
|
|||
| Drug Name |
IONIS-FB-LRx
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | IgA nephropathy [ICD-11: MF8Y] | Phase 2 | [1] | |
| Company |
Ionis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CFB messenger RNA (CFB mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04014335) A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.